For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the arrival of Vyndamax and Attruby represents a true breakthrough . These novel therapies preserve the transthyretin protein, slowing its damaging build-up and reducing the impact of the condition . Patients are now experiencing benefits in their quali